MVZ Medizinisches Labor Nord MLN
MVZ Medizinisches Labor Nord MLN is recorded as a service provider in 13 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 13 of 13 trials · Latest update first
P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy
Sponsor ROXALL Medizin GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Pitolisant Followed by an Open-Label Extension in Patients with Prader-Willi Syndrome
Sponsor Harmony Biosciences LLC
- Start (EU)
- Latest update
- Estimated end
A phase 2b, multicenter, double-blind, placebo-controlled, study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of obefazimod in subjects with moderately to severely active Crohn’s disease
Sponsor Abivax
- Start (EU)
- Latest update
- Estimated end
International, multicenter, blinded phase III clinical trial to assess the diagnostic efficacy of the skin prick test from ROXALL (SPT-RX) with different allergen extract solutions for in vivo diagnosis of IgE mediated allergies
Sponsor ROXALL Medizin GmbH
- Start (EU)
- Not reported
- Latest update
- Estimated end
Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
P3-IMU-838-RMS-02 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
P3-IMU-838-RMS-01 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from house dust mite allergy. A prospective, international, randomized, double-blind, placebo-controlled, multicentre, phase II-III trial.
Sponsor ROXALL Medizin GmbH
- Start (EU)
- Latest update
- Estimated end
A multicentre, single arm trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 13 cycles.
Sponsor Chemo Research S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 9 cycles in comparison with Desogestrel tablets 0.075 mg.
Sponsor Chemo Research S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from grass pollen allergy
Sponsor ROXALL Medizin GmbH
- Start (EU)
- Latest update
- Estimated end
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy
Sponsor ROXALL Medizin GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for MVZ Medizinisches Labor Nord MLN?
The 2026-10-09 snapshot links MVZ Medizinisches Labor Nord MLN to 13 distinct CTIS trials. Recorded services include Laboratory services, genetic testing. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for MVZ Medizinisches Labor Nord MLN?
The most frequently recorded therapeutic areas are Immunology, Neurology, Allergy, Gastroenterology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to MVZ Medizinisches Labor Nord MLN conducted?
The linked trials record locations in 18 countries, including Germany, Poland, Romania, Spain, Czechia. These are trial locations, not confirmed office locations or countries where MVZ Medizinisches Labor Nord MLN delivered services.
What can this page tell me about MVZ Medizinisches Labor Nord MLN's trial experience?
Browse 13 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under MVZ Medizinisches Labor Nord MLN. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- MVZ Medizinisches Labor Nord MLN GmbH